Most biotech companies don’t fail to raise capital because the science is wrong. They fail because investors can’t see a credible path from discovery to value creation.
In partnership with Life Science Nation, this webinar brings together investors, founders, and drug development strategists to unpack what actually makes an early-stage biotech investable beyond biology. The panel will cover how to align science, team, and capital strategy; why exit planning needs to start on day one; and the specific credibility gaps that make investors walk away.
Key learning objectives:
- What investors are really evaluating when they assess an early-stage asset and the difference between compelling biology and development readiness
- How to build the “Tripod” of science, people, and capital so they mature together instead of working against each other
- Why identifying your likely acquirer or partner early increases optionality and strengthens your pitch
- The green flags and red flags investors look for in a development plan, and the credibility gaps that undermine even strong science
- How to think beyond your next financing round anticipating shifts in regulatory environments, standard of care, and capital markets
This webinar is ideal for
- Pre-Series A to Series B biotech founders
- CSOs and CEOs
- Translational medicine leaders
- Business development leaders
- Investors evaluating early-stage assets
Speakers:
- Fran Brown, PhD, Senior Vice President, Global Head, Drug Development Science, Certara
- Geoff Fatzinger, Vice President, Regulatory Strategy, Certara
- Allen Hakimi, Managing Director, Technomark Life Sciences
- Jayanth Batchu, Senior Associate / EIR, Xontogeny
- Dr Robert Balfour, Investment Director
- Jeff Bernstein, TegMine Therapeutics
